GlassScriptPhysician profile
Graciano Avendano
NPI 1104999705
$6,773.02
in general payments reported to CMS, 2019-2025
33 companies · $1,626 in 2025
The $1,626 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $45.09 · 2021: $620 · 2022: $1,455 · 2023: $1,187 · 2024: $1,583 · 2025: $1,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,343 · Education: $53.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,342.72 |
| Education | $53.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $654.43 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $636.41 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $585.16 | 2021-2025 | Jardiance |
| Boston Scientific Corporation | $564.99 | 2022-2025 | Watchman Flx, Watchman, Avvigo Guidance System |
| Amgen INC. | $517.05 | 2021-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $380.43 | 2023-2025 | Onpattro, Amvuttra |
| Abbott Laboratories | $345.02 | 2020-2022 | |
| Novo Nordisk INC | $311.49 | 2022-2025 | Ozempic, Wegovy |
| Pfizer INC. | $296.42 | 2021-2025 | |
| Edwards Lifesciences Corporation | $242.70 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $206.09 | 2019-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $203.30 | 2021-2025 | Barostim Neo System |
| Heartflow, INC. | $194.21 | 2023-2025 | Ffrct |
| Astrazeneca Pharmaceuticals LP | $185.44 | 2021-2024 | Calquence, Farxiga |
| Janssen Pharmaceuticals, INC | $174.91 | 2021-2024 | Xarelto |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $173.31 | 2024 | Inpefa |
| Bridgebio Pharma, INC. | $158.61 | 2025 | Attruby |
| Impulse Dynamics (USA) INC. | $154.25 | 2021 | |
| Baxter Healthcare | $148.77 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor |
| Penumbra, INC. | $130.89 | 2022-2024 | Penumbra System |
| Philips North America LLC | $118.23 | 2022-2025 | (Ck7) Extended Holter, Mcot |
| Esperion Therapeutics, INC. | $90.63 | 2023-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $49.36 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $45.42 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.78 | 2025 | |
| Irhythm Technologies, INC. | $33.89 | 2022 | |
| Amarin Pharma, INC. | $28.94 | 2020-2022 | |
| Lilly USA, LLC | $20.34 | 2025 | Zepbound |
| Bardy Diagnostics, INC. | $20.00 | 2020-2021 | |
| Scpharmaceuticals INC. | $19.57 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $16.00 | 2023 | Arcalyst |
| Abiomed | $14.94 | 2025 | |
| Kestra Medical Technology Services, INC. | $14.04 | 2024 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Graciano Avendano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.